Published in Lab Business Week, December 26th, 2004
The offering is being made pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended. The sale of the notes is expected to close on November 18, 2004, subject to customary closing conditions.
Amgen estimates that the net proceeds from the offering of the notes will be approximately $1.99 billion after deducting fees and expenses. Amgen intends to use the net proceeds of the offering primarily for open market purchases of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week